APO Research
Talk to an analyst

APO RESEARCH · REPORT

Myocardial Infarction Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Myocardial Infarction Drug Industry Research Report 2026

19 December 2025138 pages

Choose your research edition.

Industry ResearchMyocardial Infarction Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Myocardial Infarction Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Myocardial Infarction Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Myocardial Infarction Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Myocardial Infarction Drug Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Myocardial Infarction Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Myocardial Infarction Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Myocardial Infarction Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Myocardial Infarction Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Myocardial Infarction Drug include LegoChem Biosciences, Inc, Lee's Pharmaceutical Holdings Limited, Laboratoires Pierre Fabre SA, Juventas Therapeutics, Inc., Immune Pharmaceuticals Inc., HUYA Bioscience International, LLC, Human Stem Cells Institute, Hemostemix Ltd and FibroGen, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Myocardial Infarction Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Myocardial Infarction Drug Market by Company

LegoChem Biosciences, Inc

Lee's Pharmaceutical Holdings Limited

Laboratoires Pierre Fabre SA

Juventas Therapeutics, Inc.

Immune Pharmaceuticals Inc.

HUYA Bioscience International, LLC

Human Stem Cells Institute

Hemostemix Ltd

FibroGen, Inc.

Cynata Therapeutics Limited

CSL Limited

Compugen Ltd.

Celyad SA

CellProthera

Capricor Therapeutics, Inc.

Biscayne Pharmaceuticals, Inc.

BioCardia, Inc.

Myocardial Infarction Drug Segment by Type

AMRS-001

ANG-4011

Balixafortide

CAP-1002

Cenderitide

JVS-200

KR-33028

Others

Myocardial Infarction Drug Segment by Application

Research Center

Hospital

Clinic

Myocardial Infarction Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myocardial Infarction Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Myocardial Infarction Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myocardial Infarction Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Myocardial Infarction Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Myocardial Infarction Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Myocardial Infarction Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Myocardial Infarction Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Myocardial Infarction Drug Sales (W Units) of Manufacturers (2021-2026) Table 7. Global Myocardial Infarction Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Myocardial Infarction Drug Revenue of Manufacturers (2021-2026) Table 9. Global Myocardial Infarction Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Myocardial Infarction Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Myocardial Infarction Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Myocardial Infarction Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Myocardial Infarction Drug, Product Type & Application Table 14. Global Myocardial Infarction Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Myocardial Infarction Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. LegoChem Biosciences, Inc Company Information Table 19. LegoChem Biosciences, Inc Business Overview Table 20. LegoChem Biosciences, Inc Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. LegoChem Biosciences, Inc Myocardial Infarction Drug Product Portfolio Table 22. LegoChem Biosciences, Inc Recent Developments Table 23. Lee's Pharmaceutical Holdings Limited Company Information Table 24. Lee's Pharmaceutical Holdings Limited Business Overview Table 25. Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Product Portfolio Table 27. Lee's Pharmaceutical Holdings Limited Recent Developments Table 28. Laboratoires Pierre Fabre SA Company Information Table 29. Laboratoires Pierre Fabre SA Business Overview Table 30. Laboratoires Pierre Fabre SA Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Laboratoires Pierre Fabre SA Myocardial Infarction Drug Product Portfolio Table 32. Laboratoires Pierre Fabre SA Recent Developments Table 33. Juventas Therapeutics, Inc. Company Information Table 34. Juventas Therapeutics, Inc. Business Overview Table 35. Juventas Therapeutics, Inc. Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Juventas Therapeutics, Inc. Myocardial Infarction Drug Product Portfolio Table 37. Juventas Therapeutics, Inc. Recent Developments Table 38. Immune Pharmaceuticals Inc. Company Information Table 39. Immune Pharmaceuticals Inc. Business Overview Table 40. Immune Pharmaceuticals Inc. Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Immune Pharmaceuticals Inc. Myocardial Infarction Drug Product Portfolio Table 42. Immune Pharmaceuticals Inc. Recent Developments Table 43. HUYA Bioscience International, LLC Company Information Table 44. HUYA Bioscience International, LLC Business Overview Table 45. HUYA Bioscience International, LLC Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. HUYA Bioscience International, LLC Myocardial Infarction Drug Product Portfolio Table 47. HUYA Bioscience International, LLC Recent Developments Table 48. Human Stem Cells Institute Company Information Table 49. Human Stem Cells Institute Business Overview Table 50. Human Stem Cells Institute Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Human Stem Cells Institute Myocardial Infarction Drug Product Portfolio Table 52. Human Stem Cells Institute Recent Developments Table 53. Hemostemix Ltd Company Information Table 54. Hemostemix Ltd Business Overview Table 55. Hemostemix Ltd Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Hemostemix Ltd Myocardial Infarction Drug Product Portfolio Table 57. Hemostemix Ltd Recent Developments Table 58. FibroGen, Inc. Company Information Table 59. FibroGen, Inc. Business Overview Table 60. FibroGen, Inc. Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. FibroGen, Inc. Myocardial Infarction Drug Product Portfolio Table 62. FibroGen, Inc. Recent Developments Table 63. Cynata Therapeutics Limited Company Information Table 64. Cynata Therapeutics Limited Business Overview Table 65. Cynata Therapeutics Limited Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Cynata Therapeutics Limited Myocardial Infarction Drug Product Portfolio Table 67. Cynata Therapeutics Limited Recent Developments Table 68. CSL Limited Company Information Table 69. CSL Limited Business Overview Table 70. CSL Limited Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. CSL Limited Myocardial Infarction Drug Product Portfolio Table 72. CSL Limited Recent Developments Table 73. Compugen Ltd. Company Information Table 74. Compugen Ltd. Business Overview Table 75. Compugen Ltd. Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Compugen Ltd. Myocardial Infarction Drug Product Portfolio Table 77. Compugen Ltd. Recent Developments Table 78. Celyad SA Company Information Table 79. Celyad SA Business Overview Table 80. Celyad SA Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Celyad SA Myocardial Infarction Drug Product Portfolio Table 82. Celyad SA Recent Developments Table 83. CellProthera Company Information Table 84. CellProthera Business Overview Table 85. CellProthera Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. CellProthera Myocardial Infarction Drug Product Portfolio Table 87. CellProthera Recent Developments Table 88. Capricor Therapeutics, Inc. Company Information Table 89. Capricor Therapeutics, Inc. Business Overview Table 90. Capricor Therapeutics, Inc. Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Capricor Therapeutics, Inc. Myocardial Infarction Drug Product Portfolio Table 92. Capricor Therapeutics, Inc. Recent Developments Table 93. Biscayne Pharmaceuticals, Inc. Company Information Table 94. Biscayne Pharmaceuticals, Inc. Business Overview Table 95. Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Product Portfolio Table 97. Biscayne Pharmaceuticals, Inc. Recent Developments Table 98. BioCardia, Inc. Company Information Table 99. BioCardia, Inc. Business Overview Table 100. BioCardia, Inc. Myocardial Infarction Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. BioCardia, Inc. Myocardial Infarction Drug Product Portfolio Table 102. BioCardia, Inc. Recent Developments Table 103. Global Myocardial Infarction Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Myocardial Infarction Drug Sales by Region (2021-2026) & (W Units) Table 105. Global Myocardial Infarction Drug Sales Market Share by Region (2021-2026) Table 106. Global Myocardial Infarction Drug Sales by Region (2027-2032) & (W Units) Table 107. Global Myocardial Infarction Drug Sales Market Share by Region (2027-2032) Table 108. Global Myocardial Infarction Drug Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Myocardial Infarction Drug Revenue Market Share by Region (2021-2026) Table 110. Global Myocardial Infarction Drug Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Myocardial Infarction Drug Revenue Market Share by Region (2027-2032) Table 112. North America Myocardial Infarction Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 114. North America Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 115. North America Myocardial Infarction Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Myocardial Infarction Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Myocardial Infarction Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 119. Europe Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 120. Europe Myocardial Infarction Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Myocardial Infarction Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Myocardial Infarction Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 124. Asia Pacific Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 125. Asia Pacific Myocardial Infarction Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Myocardial Infarction Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Myocardial Infarction Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 129. South America Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 130. South America Myocardial Infarction Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Myocardial Infarction Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Myocardial Infarction Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 134. Middle East and Africa Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 135. Middle East and Africa Myocardial Infarction Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Myocardial Infarction Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Myocardial Infarction Drug Sales by Type (2021-2026) & (W Units) Table 138. Global Myocardial Infarction Drug Sales by Type (2027-2032) & (W Units) Table 139. Global Myocardial Infarction Drug Sales Market Share by Type (2021-2026) Table 140. Global Myocardial Infarction Drug Sales Market Share by Type (2027-2032) Table 141. Global Myocardial Infarction Drug Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Myocardial Infarction Drug Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Myocardial Infarction Drug Revenue Market Share by Type (2021-2026) Table 144. Global Myocardial Infarction Drug Revenue Market Share by Type (2027-2032) Table 145. Global Myocardial Infarction Drug Price by Type (2021-2026) & (US$/Unit) Table 146. Global Myocardial Infarction Drug Price by Type (2027-2032) & (US$/Unit) Table 147. Global Myocardial Infarction Drug Sales by Application (2021-2026) & (W Units) Table 148. Global Myocardial Infarction Drug Sales by Application (2027-2032) & (W Units) Table 149. Global Myocardial Infarction Drug Sales Market Share by Application (2021-2026) Table 150. Global Myocardial Infarction Drug Sales Market Share by Application (2027-2032) Table 151. Global Myocardial Infarction Drug Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Myocardial Infarction Drug Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Myocardial Infarction Drug Revenue Market Share by Application (2021-2026) Table 154. Global Myocardial Infarction Drug Revenue Market Share by Application (2027-2032) Table 155. Global Myocardial Infarction Drug Price by Application (2021-2026) & (US$/Unit) Table 156. Global Myocardial Infarction Drug Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Myocardial Infarction Drug Distributors List Table 160. Myocardial Infarction Drug Customers List Table 161. Myocardial Infarction Drug Industry Trends Table 162. Myocardial Infarction Drug Industry Drivers Table 163. Myocardial Infarction Drug Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Myocardial Infarction Drug Product Image Figure 5. Global Myocardial Infarction Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Myocardial Infarction Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Myocardial Infarction Drug Sales (2021-2032) & (W Units) Figure 8. Global Myocardial Infarction Drug Average Price (US$/Unit) & (2021-2032) Figure 9. AMRS-001 Product Image Figure 10. ANG-4011 Product Image Figure 11. Balixafortide Product Image Figure 12. CAP-1002 Product Image Figure 13. Cenderitide Product Image Figure 14. JVS-200 Product Image Figure 15. KR-33028 Product Image Figure 16. Others Product Image Figure 17. Research Center Product Image Figure 18. Hospital Product Image Figure 19. Clinic Product Image Figure 20. Global Myocardial Infarction Drug Revenue Share by Manufacturers in 2025 Figure 21. Global Manufacturers of Myocardial Infarction Drug, Manufacturing Sites & Headquarters Figure 22. Global Top 5 and 10 Myocardial Infarction Drug Players Market Share by Revenue in 2025 Figure 23. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. Global Myocardial Infarction Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 25. Global Myocardial Infarction Drug Sales by Region in 2025 Figure 26. Global Myocardial Infarction Drug Revenue by Region in 2025 Figure 27. North America Myocardial Infarction Drug Market Size by Country in 2025 Figure 28. North America Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 29. North America Myocardial Infarction Drug Revenue Market Share by Country (2021-2032) Figure 30. United States Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Canada Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Myocardial Infarction Drug Market Size by Country in 2025 Figure 33. Europe Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 34. Europe Myocardial Infarction Drug Revenue Market Share by Country (2021-2032) Figure 35. Germany Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Nordic Countries Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Myocardial Infarction Drug Market Size by Country in 2025 Figure 42. Asia Pacific Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Myocardial Infarction Drug Revenue Market Share by Country (2021-2032) Figure 44. China Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. China Taiwan Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Myocardial Infarction Drug Market Size by Country in 2025 Figure 53. South America Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 54. South America Myocardial Infarction Drug Revenue Market Share by Country (2021-2032) Figure 55. Mexico Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Brazil Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Myocardial Infarction Drug Market Size by Country in 2025 Figure 59. Middle East and Africa Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Myocardial Infarction Drug Revenue Market Share by Country (2021-2032) Figure 61. Turkey Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Saudi Arabia Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. UAE Myocardial Infarction Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Global Myocardial Infarction Drug Sales Market Share by Type (2021-2032) Figure 65. Global Myocardial Infarction Drug Revenue Market Share by Type (2021-2032) Figure 66. Global Myocardial Infarction Drug Price (US$/Unit) by Type (2021-2032) Figure 67. Global Myocardial Infarction Drug Sales Market Share by Application (2021-2032) Figure 68. Global Myocardial Infarction Drug Revenue Market Share by Application (2021-2032) Figure 69. Global Myocardial Infarction Drug Price (US$/Unit) by Application (2021-2032) Figure 70. Myocardial Infarction Drug Value Chain Figure 71. Myocardial Infarction Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Myocardial Infarction Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • AMRS-001
  • ANG-4011
  • Balixafortide
  • CAP-1002
  • Cenderitide
  • JVS-200
  • KR-33028
  • Others
Applications
  • Research Center
  • Hospital
  • Clinic
Companies covered
  • LegoChem Biosciences, Inc
  • Lee's Pharmaceutical Holdings Limited
  • Laboratoires Pierre Fabre SA
  • Juventas Therapeutics, Inc.
  • Immune Pharmaceuticals Inc.
  • HUYA Bioscience International, LLC
  • Human Stem Cells Institute
  • Hemostemix Ltd
  • FibroGen, Inc.
  • Cynata Therapeutics Limited
  • CSL Limited
  • Compugen Ltd.
  • Celyad SA
  • CellProthera
  • Capricor Therapeutics, Inc.
  • Biscayne Pharmaceuticals, Inc.
  • BioCardia, Inc.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Myocardial Infarction Drug Market Size (2021-2032)
  4. 2.2.2 Global Myocardial Infarction Drug Sales (2021-2032)
  5. 2.2.3 Global Myocardial Infarction Drug Market Average Price (2021-2032)
  6. 2.3 Myocardial Infarction Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 AMRS-001
  9. 2.3.3 ANG-4011
  10. 2.3.4 Balixafortide
  11. 2.3.5 CAP-1002
  12. 2.3.6 Cenderitide
  13. 2.3.7 JVS-200
  14. 2.3.8 KR-33028
  15. 2.3.9 Others
  16. 2.4 Myocardial Infarction Drug by Application
  17. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  18. 2.4.2 Research Center
  19. 2.4.3 Hospital
  20. 2.4.4 Clinic
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Myocardial Infarction Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Myocardial Infarction Drug Sales (W Units) of Manufacturers (2021-2026)
  3. 3.3 Global Myocardial Infarction Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Myocardial Infarction Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Myocardial Infarction Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Myocardial Infarction Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Myocardial Infarction Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Myocardial Infarction Drug, Established Date
  9. 3.9 Global Myocardial Infarction Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 LegoChem Biosciences, Inc
  2. 4.1.1 LegoChem Biosciences, Inc Company Information
  3. 4.1.2 LegoChem Biosciences, Inc Business Overview
  4. 4.1.3 LegoChem Biosciences, Inc Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 LegoChem Biosciences, Inc Myocardial Infarction Drug Product Portfolio
  6. 4.1.5 LegoChem Biosciences, Inc Recent Developments
  7. 4.2 Lee's Pharmaceutical Holdings Limited
  8. 4.2.1 Lee's Pharmaceutical Holdings Limited Company Information
  9. 4.2.2 Lee's Pharmaceutical Holdings Limited Business Overview
  10. 4.2.3 Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Product Portfolio
  12. 4.2.5 Lee's Pharmaceutical Holdings Limited Recent Developments
  13. 4.3 Laboratoires Pierre Fabre SA
  14. 4.3.1 Laboratoires Pierre Fabre SA Company Information
  15. 4.3.2 Laboratoires Pierre Fabre SA Business Overview
  16. 4.3.3 Laboratoires Pierre Fabre SA Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Laboratoires Pierre Fabre SA Myocardial Infarction Drug Product Portfolio
  18. 4.3.5 Laboratoires Pierre Fabre SA Recent Developments
  19. 4.4 Juventas Therapeutics, Inc.
  20. 4.4.1 Juventas Therapeutics, Inc. Company Information
  21. 4.4.2 Juventas Therapeutics, Inc. Business Overview
  22. 4.4.3 Juventas Therapeutics, Inc. Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Juventas Therapeutics, Inc. Myocardial Infarction Drug Product Portfolio
  24. 4.4.5 Juventas Therapeutics, Inc. Recent Developments
  25. 4.5 Immune Pharmaceuticals Inc.
  26. 4.5.1 Immune Pharmaceuticals Inc. Company Information
  27. 4.5.2 Immune Pharmaceuticals Inc. Business Overview
  28. 4.5.3 Immune Pharmaceuticals Inc. Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Immune Pharmaceuticals Inc. Myocardial Infarction Drug Product Portfolio
  30. 4.5.5 Immune Pharmaceuticals Inc. Recent Developments
  31. 4.6 HUYA Bioscience International, LLC
  32. 4.6.1 HUYA Bioscience International, LLC Company Information
  33. 4.6.2 HUYA Bioscience International, LLC Business Overview
  34. 4.6.3 HUYA Bioscience International, LLC Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 HUYA Bioscience International, LLC Myocardial Infarction Drug Product Portfolio
  36. 4.6.5 HUYA Bioscience International, LLC Recent Developments
  37. 4.7 Human Stem Cells Institute
  38. 4.7.1 Human Stem Cells Institute Company Information
  39. 4.7.2 Human Stem Cells Institute Business Overview
  40. 4.7.3 Human Stem Cells Institute Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Human Stem Cells Institute Myocardial Infarction Drug Product Portfolio
  42. 4.7.5 Human Stem Cells Institute Recent Developments
  43. 4.8 Hemostemix Ltd
  44. 4.8.1 Hemostemix Ltd Company Information
  45. 4.8.2 Hemostemix Ltd Business Overview
  46. 4.8.3 Hemostemix Ltd Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hemostemix Ltd Myocardial Infarction Drug Product Portfolio
  48. 4.8.5 Hemostemix Ltd Recent Developments
  49. 4.9 FibroGen, Inc.
  50. 4.9.1 FibroGen, Inc. Company Information
  51. 4.9.2 FibroGen, Inc. Business Overview
  52. 4.9.3 FibroGen, Inc. Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 FibroGen, Inc. Myocardial Infarction Drug Product Portfolio
  54. 4.9.5 FibroGen, Inc. Recent Developments
  55. 4.10 Cynata Therapeutics Limited
  56. 4.10.1 Cynata Therapeutics Limited Company Information
  57. 4.10.2 Cynata Therapeutics Limited Business Overview
  58. 4.10.3 Cynata Therapeutics Limited Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Cynata Therapeutics Limited Myocardial Infarction Drug Product Portfolio
  60. 4.10.5 Cynata Therapeutics Limited Recent Developments
  61. 4.11 CSL Limited
  62. 4.11.1 CSL Limited Company Information
  63. 4.11.2 CSL Limited Business Overview
  64. 4.11.3 CSL Limited Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 CSL Limited Myocardial Infarction Drug Product Portfolio
  66. 4.11.5 CSL Limited Recent Developments
  67. 4.12 Compugen Ltd.
  68. 4.12.1 Compugen Ltd. Company Information
  69. 4.12.2 Compugen Ltd. Business Overview
  70. 4.12.3 Compugen Ltd. Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Compugen Ltd. Myocardial Infarction Drug Product Portfolio
  72. 4.12.5 Compugen Ltd. Recent Developments
  73. 4.13 Celyad SA
  74. 4.13.1 Celyad SA Company Information
  75. 4.13.2 Celyad SA Business Overview
  76. 4.13.3 Celyad SA Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Celyad SA Myocardial Infarction Drug Product Portfolio
  78. 4.13.5 Celyad SA Recent Developments
  79. 4.14 CellProthera
  80. 4.14.1 CellProthera Company Information
  81. 4.14.2 CellProthera Business Overview
  82. 4.14.3 CellProthera Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 CellProthera Myocardial Infarction Drug Product Portfolio
  84. 4.14.5 CellProthera Recent Developments
  85. 4.15 Capricor Therapeutics, Inc.
  86. 4.15.1 Capricor Therapeutics, Inc. Company Information
  87. 4.15.2 Capricor Therapeutics, Inc. Business Overview
  88. 4.15.3 Capricor Therapeutics, Inc. Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Capricor Therapeutics, Inc. Myocardial Infarction Drug Product Portfolio
  90. 4.15.5 Capricor Therapeutics, Inc. Recent Developments
  91. 4.16 Biscayne Pharmaceuticals, Inc.
  92. 4.16.1 Biscayne Pharmaceuticals, Inc. Company Information
  93. 4.16.2 Biscayne Pharmaceuticals, Inc. Business Overview
  94. 4.16.3 Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Product Portfolio
  96. 4.16.5 Biscayne Pharmaceuticals, Inc. Recent Developments
  97. 4.17 BioCardia, Inc.
  98. 4.17.1 BioCardia, Inc. Company Information
  99. 4.17.2 BioCardia, Inc. Business Overview
  100. 4.17.3 BioCardia, Inc. Myocardial Infarction Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 BioCardia, Inc. Myocardial Infarction Drug Product Portfolio
  102. 4.17.5 BioCardia, Inc. Recent Developments
5 Global Myocardial Infarction Drug Market Scenario by Region
  1. 5.1 Global Myocardial Infarction Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Myocardial Infarction Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Myocardial Infarction Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Myocardial Infarction Drug Sales by Region: 2027-2032
  5. 5.3 Global Myocardial Infarction Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Myocardial Infarction Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Myocardial Infarction Drug Revenue by Region: 2027-2032
  8. 5.4 North America Myocardial Infarction Drug Market Facts & Figures by Country
  9. 5.4.1 North America Myocardial Infarction Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Myocardial Infarction Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Myocardial Infarction Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Myocardial Infarction Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Myocardial Infarction Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Myocardial Infarction Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Myocardial Infarction Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Myocardial Infarction Drug Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Myocardial Infarction Drug Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Myocardial Infarction Drug Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Myocardial Infarction Drug Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Myocardial Infarction Drug Market Facts & Figures by Country
  36. 5.7.1 South America Myocardial Infarction Drug Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Myocardial Infarction Drug Sales by Country (2021-2032)
  38. 5.7.3 South America Myocardial Infarction Drug Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.8 Middle East and Africa Myocardial Infarction Drug Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Myocardial Infarction Drug Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Myocardial Infarction Drug Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Myocardial Infarction Drug Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Myocardial Infarction Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Myocardial Infarction Drug Sales by Type (2021-2032) & (W Units)
  3. 6.1.2 Global Myocardial Infarction Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Myocardial Infarction Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Myocardial Infarction Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Myocardial Infarction Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Myocardial Infarction Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Myocardial Infarction Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Myocardial Infarction Drug Sales by Application (2021-2032) & (W Units)
  3. 7.1.2 Global Myocardial Infarction Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Myocardial Infarction Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Myocardial Infarction Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Myocardial Infarction Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Myocardial Infarction Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Myocardial Infarction Drug Value Chain Analysis
  2. 8.1.1 Myocardial Infarction Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Myocardial Infarction Drug Production Mode & Process
  5. 8.2 Myocardial Infarction Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Myocardial Infarction Drug Distributors
  8. 8.2.3 Myocardial Infarction Drug Customers
9 Global Myocardial Infarction Drug Analyzing Market Dynamics
  1. 9.1 Myocardial Infarction Drug Industry Trends
  2. 9.2 Myocardial Infarction Drug Industry Drivers
  3. 9.3 Myocardial Infarction Drug Industry Opportunities and Challenges
  4. 9.4 Myocardial Infarction Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst